| | Abbott Progresses with Absorb in Japan Analyst Blog We believe Abbott Lab diversification in varied business lines will enable the company to counter the challenging business environment and maintain topline growth. | |
| | Abbott Labs HPV Test in Canada ... with weak economic conditions and a mixed global economy. Abbott Labs currently carries a Zacks Rank 3 . Right now AtriCure Inc. and TranS1 Inc look well placed with a Zacks Rank 2 . | |
| | Abbott Lab HPV Test in Canada Analyst Blog NASDAQ May 31 2013 Abbott Labs currently carries a Zacks Rank 3 . Right now AtriCure Inc. and TranS1 Inc look well placed with a Zacks Rank 2 . | |
| | AtriCure Rating Increased to Hold at TheStreet AtriCure Inc. is a medical device company. The Company is developing manufacturing and selling cardiac surgical ablation systems designed to create lesions or scars in cardiac or heart tissue. | |
| | Covidiens ENB Adopted by ACCP Zacks.com May 23 2013 While we strongly recommend investors to avoid this stock other medical stocks such as Conceptus Atricure and Myriad Genetics warrant a look. | |
| | CE Mark for Abbott Xience Xpedition 48 Analyst Blog ... developed markets in 2013 coupled with weak economic conditionsand a mixed global economy. Abbott Labs currently carries a Zacks Rank 3 . | |
| | AtriCure Upgraded by TheStreet to quotHoldquot On average analysts predict that AtriCure will post 0.42 earnings per share for the current fiscal year. AtriCure Inc. is a medical device company. The Company is developing manufacturing and selling cardiac surgical ablation systems designed to ... | |
| | AtriCure Inc. Stock Upgraded AtriCure Inc. a medical device company develops manufactures and sells cardiac surgical ablation systems designed to create precise lesions or scars in cardiac tissue. | |
| | CE Mark for STJ ILUMIEN OPTIS Analyst Blog NASDAQ.com Medical devices major St. Jude Medical Inc. has won CE Mark approval for its ILUMIEN OPTIS Percutaneous Coronary Intervention Optimization System. | |
| | CE Mark for STJs ILUMIEN OPTIS Zacks.com May 17 2013 Medical devices major St. Jude Medical Inc. has won CE Mark approval for its ILUMIEN OPTIS Percutaneous Coronary Intervention Optimization System. | |
| | CE Mark for STJ Ellipse and Assura Analyst Blog NASDAQ.com St. Jude Medical Inc. has won CE Mark approval for its Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators . | |
| | CE Mark for STJs Ellipse amp Assura Zacks.com May 13 2013 St. Jude Medical Inc. has won CE Mark approval for its Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators . | |
| | AtriCure reports a loss still beats estimates AtriCure Inc. reported a firstquarter loss but still beat analyst expectations for earnings and revenue as training and education efforts helped it capture market share. | |
| | AtriCure Releases Quarterly Earnings Results Misses Estimates By ... Daily Political May 2 2013 AtriCure has a 52 week low of 5.90 and a 52 week high of 9.98. The stock 50day moving average is currently 8.12. The company market cap is 165.1 million. | |
| | ATRICURE INC. AtriCure Reports First Quarter 2013 Financial Results 4traders May 2 2013 AtriCure Inc. a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation or Afib and systems for the exclusion of the left atrial appendage today announced ... AtriCure Releases Quarterly Earnings Results Misses Estimates By ... Daily Political | |
| |
0.78% 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Advice
